When an oncology R&D landscape starts getting crowded and highly competitive, how do you go about working out clinically meaningful differences between compounds in development?
After all, there are often a myriad of small differences and nuances in the preclinical approach that may or may not be useful when it comes to the clinic.
Sometimes design matters, whether this be in the way the molecules are built or function, perhaps in tumour types that are selected for study, while at other times trial design can impact outcome. In short, much like a 3D chess game it can get complicated pretty fast.
One such area that has been receiving increased attention lately and also has a lot of complexity to consider is the CD47-SIRPα pathway.
Last week we covered some of the key basics in a primer exploring the science in Part 1 of this mini-series.
Tomorrow we will post Part 3, which focuses on candid comments from researchers and CEOs in this niche, but before we get there it’s time to look at key clinical perspectives, as well as some of the nuances from related pathways that may be important factors to consider.